|
|
|||
| "The important thing is not to stop questioning. Curiosity has its own reason for existing. One cannot help but be in awe when he contemplates the mysteries of eternity, of life, of the marvelous structure of reality. It is enough if one tries merely to comprehend a little of this mystery every day. Never lose a holy curiosity." ---- Albert Einstein We believe that research is needed to improve Diabetes Care and we have a commitment to participation in clinical research projects to advance knowledge of Diabetes. We have participated in research projects, which we feel offer significant benefits to our patients and advance the cause of effective Diabetes care. __________________________________________________________________________________ SAVOR-TIMI 53 Sponsor: Astra Zeneca Purpose: to determine whether treatment with saxagliptin compared to placebo will result in reduction of cardiovascular (CV) death, non-fatal myocardial infarction (MI) or non-fatal ischemic stroke. __________________________________________________________________________________ DEFEND-1 Sponsor: Tolerx, Inc. Purpose: to find out if an 8-day series of otelixizumab infusions leads to greater improvement in insulin secretion as compared with placebo in newly diagnosed type 1 diabetes patients. __________________________________________________________________________________ Johnson & Johnson 28431754-DIA-3004 Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Purpose: to assess the effect of canagliflozin relative to placebo in subjects with Type 2 Diabetes with inadequate glycemic control and who have moderate renal impairment. __________________________________________________________________________________ TAKEDA SYR-322_305 Sponsor: Takeda Global Research & Development Center, Inc. Purpose: To assess the efficacy and safety of alogliptin plus metformin compared to glipizide plus metformin in subjects with type 2 diabetes mellitus whose blood sugar level is inadequately controlled on metformin therapy. The duration of this study will be approximately 2 years. ___________________________________________________________________________________ LANTU_L_04695 START Sponsor: Sanofi aventis Purpose: To evaluate two approaches of blood glucose monitoring and insulin titration (patient-managed vs. health care professional) in type 2 diabetes mellitus patients while receiving the addition of 1 injection of insulin glulisine (Apidra) at breakfast following optimization of insulin glargine (Lantus). Insulin glargine (Lantus) and insulin glulisine (Apidra) will be provided for the study. Duration of the study is 24 months. __________________________________________________________________________________ DAPA 18 D1690= C00018 Sponsor: AstraZeneca Purpose: This study is designed to evaluate the efficacy and safety of dapagliflozin in lowering blood glucose, body weight and blood pressure compared to placebo and usual care in patients who have type 2 diabetes, cardiovascular disease and hypertension that have inadequate glycemic control. __________________________________________________________________________________ CANTATA-MP Trial- Johnson & Johnson 28431754-DIA-3012 Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Purpose: to evaluate the efficacy and safety of two different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus that are receiving treatment with metformin and pioglitazone and have inadequate glycemic (blood sugar) control. | |||